1256359-03-1 Usage
Description
2-Benzyloxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine is an organic compound characterized by its unique molecular structure, which features a pyridine ring with a benzyloxy group at the 2nd position and a tetramethyl-1,3,2-dioxaborolan-2-yl group at the 4th position. 2-Benzyloxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine is known for its potential applications in the pharmaceutical and chemical industries due to its reactivity and structural properties.
Uses
Used in Pharmaceutical Industry:
2-Benzyloxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine is used as a reagent for the preparation of fatty acid synthase (FASN) inhibitors. These inhibitors are crucial in the treatment of various diseases, including cancer, as they target the enzyme responsible for the synthesis of fatty acids, which are essential for the growth and survival of cancer cells.
Used in Chemical Synthesis:
In the field of chemical synthesis, 2-Benzyloxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine serves as a versatile building block for the development of new compounds with potential applications in various industries. Its unique structure allows for further functionalization and modification, making it a valuable asset in the synthesis of complex organic molecules.
Check Digit Verification of cas no
The CAS Registry Mumber 1256359-03-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,5,6,3,5 and 9 respectively; the second part has 2 digits, 0 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1256359-03:
(9*1)+(8*2)+(7*5)+(6*6)+(5*3)+(4*5)+(3*9)+(2*0)+(1*3)=161
161 % 10 = 1
So 1256359-03-1 is a valid CAS Registry Number.
1256359-03-1Relevant articles and documents
THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS
-
Page/Page column 128; 130, (2014/06/11)
Thienopyridone compounds of formula (I) or a salt thereof, pharmaceutical compositions containing such compounds and their use in therapy, in particular in the treatment of diseases or conditions for which a bromodomain inhibitor is indicated.
